Precision BioSciences (NASDAQ:DTIL) Posts Quarterly Earnings Results, Misses Estimates By $0.46 EPS

Precision BioSciences (NASDAQ:DTIL) announced its quarterly earnings results on Thursday. The company reported ($1.26) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.80) by ($0.46), FiscalAI reports. Precision BioSciences had a negative net margin of 96.73% and a negative return on equity of 67.70%.

Precision BioSciences Stock Performance

NASDAQ DTIL traded up $0.07 on Friday, hitting $7.49. 240,103 shares of the stock were exchanged, compared to its average volume of 341,234. The company has a market capitalization of $193.24 million, a PE ratio of -2.67 and a beta of 1.27. The company has a debt-to-equity ratio of 0.29, a current ratio of 14.02 and a quick ratio of 14.02. The business’s fifty day moving average is $7.36 and its 200 day moving average is $6.33. Precision BioSciences has a 52 week low of $3.53 and a 52 week high of $9.62.

Wall Street Analyst Weigh In

DTIL has been the topic of several analyst reports. Weiss Ratings reissued a “sell (d-)” rating on shares of Precision BioSciences in a research report on Wednesday. HC Wainwright restated a “buy” rating on shares of Precision BioSciences in a report on Monday, August 3rd. JonesTrading reaffirmed a “buy” rating and issued a $30.00 target price on shares of Precision BioSciences in a research report on Friday, April 17th. Wall Street Zen lowered Precision BioSciences from a “hold” rating to a “sell” rating in a report on Saturday. Finally, Oppenheimer started coverage on Precision BioSciences in a research report on Tuesday, June 9th. They set an “outperform” rating and a $20.00 price target for the company. Four equities research analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $32.25.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the company. Bleichroeder LP raised its holdings in shares of Precision BioSciences by 54.7% in the 4th quarter. Bleichroeder LP now owns 1,662,500 shares of the company’s stock valued at $6,916,000 after purchasing an additional 587,500 shares during the period. Boothbay Fund Management LLC grew its holdings in Precision BioSciences by 497.1% during the fourth quarter. Boothbay Fund Management LLC now owns 1,066,050 shares of the company’s stock worth $4,435,000 after purchasing an additional 887,515 shares during the period. Lynx1 Capital Management LP increased its position in Precision BioSciences by 0.6% during the third quarter. Lynx1 Capital Management LP now owns 1,042,596 shares of the company’s stock worth $5,755,000 after buying an additional 6,545 shares during the last quarter. Alyeska Investment Group L.P. acquired a new position in Precision BioSciences during the fourth quarter worth approximately $3,320,000. Finally, Vanguard Group Inc. raised its stake in Precision BioSciences by 21.5% in the third quarter. Vanguard Group Inc. now owns 492,596 shares of the company’s stock valued at $2,719,000 after buying an additional 87,242 shares during the period. 37.99% of the stock is currently owned by institutional investors and hedge funds.

About Precision BioSciences

Precision BioSciences is a clinical‐stage genome editing company that leverages its proprietary ARCUS platform to develop targeted gene therapies. ARCUS, an engineered nuclease derived from a naturally occurring enzyme, enables precise DNA modifications for both in vivo and ex vivo applications. The company’s pipeline spans genetic diseases—including rare monogenic disorders—and immuno‐oncology, where it is advancing allogeneic cell therapy candidates designed to address hematologic malignancies and solid tumors.

Founded in 2006 as a spin‐out from research at the University of North Carolina, Precision BioSciences is headquartered in Durham, North Carolina, with additional research and manufacturing capabilities located in the Research Triangle Park area.